Crestchem Reports 18% Revenue Growth, Net Profit Flat

Revenue from operations for Crestchem Limited rose 18.06% to ₹29.61 crore in FY 2026.
Net profit after tax saw a marginal decline of 0.48% to ₹2.71 crore.

Reader Takeaway: Revenue growth driven by expansion, but margin pressure from rising costs. Dividend offers shareholder return.

What just happened

Crestchem Limited announced its audited financial results for the fiscal year 2026. The company reported an 18.06% increase in revenue from operations, reaching ₹29.61 crore. However, its profit after tax saw a slight decrease of 0.48%, closing at ₹2.71 crore. This was largely due to a significant 21.27% jump in total expenses to ₹26.51 crore. The company also recommended a final dividend of ₹1.50 per equity share and incorporated a new subsidiary, Oleo Biosciences Private Limited, in which it holds a 75% stake. An investment of up to ₹2.25 crore has been approved for this new entity.

Why this matters

For investors, the 18% revenue growth signals continued business expansion. However, the flat net profit, despite higher sales, indicates pressure on margins due to rising operational costs. The recommended dividend provides a direct return to shareholders. The formation of a new subsidiary opens avenues for future growth, but its current lack of operations is a watch point. Management continuity through reappointments offers stability.

The backstory

In the previous fiscal year (FY 2025), Crestchem had reported revenue of ₹25.08 crore and a net profit of ₹2.73 crore. The company has been focused on expanding its business volumes, as evidenced by the top-line growth. The current financial year's results show a divergence between revenue growth and profitability, highlighting the impact of increasing expenditure.

What changes now

Investors will be keen to see how Crestchem manages its cost structure in the upcoming financial year to improve profitability. The performance and operational ramp-up of Oleo Biosciences Private Limited will be crucial for future growth prospects. The dividend payout is a positive step for shareholders seeking income.

Risks to watch

The primary risk identified is margin pressure, as expenses grew faster than revenue. The newly formed subsidiary, Oleo Biosciences, currently has no commercial operations, meaning its contribution to revenue is yet to materialize. Investors should monitor the effective deployment of the ₹2.25 crore investment in the subsidiary and its path to profitability.

Peer comparison

While specific peer data isn't provided in the filing, companies in the chemical sector often face similar challenges with managing raw material costs and operational expenses. Crestchem's revenue growth is positive, but its ability to translate this into improved profits will be key when compared to industry benchmarks.

Context metrics (time-bound)

• Revenue Growth (FY26 vs FY25): +18.06% (₹29.61 crore vs ₹25.08 crore)
• Net Profit Change (FY26 vs FY25): -0.48% (₹2.71 crore vs ₹2.73 crore)
• Expense Growth (FY26 vs FY25): +21.27% (₹26.51 crore vs ₹21.86 crore)
• Dividend Recommended: ₹1.50 per share
• Subsidiary Ownership: 75% in Oleo Biosciences Private Limited

What to track next

Investors should track the company's quarterly results to observe cost management strategies and the progress of Oleo Biosciences Private Limited. The successful integration and operationalization of the subsidiary will be critical indicators for future performance.